ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Genetics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1588646
GNG7 as a tumor-suppressor gene in lung adenocarcinoma: Implications for prognosis and immune-based therapies
Provisionally accepted
Kexin Luo1
Meihan Liu1Zhongqin Peng2Haiyang Zhao2Guoyi Li2
Yuanze Cai3Yumeng Lei4
Hongpan Zhang2*
Yongsheng Zhao2*- 1Affiliated Hospital of North Sichuan Medical College, Nanchong, China
- 2Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China
- 3North Sichuan Medical College, Nanchong, Sichuan Province, China
- 4Guizhou Medical University, Guiyang, Guizhou Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Lung cancer ranks among the cancers with the highest global incidence and mortality rates, mainly due to the absence of noticeable symptoms in its early stages, lung cancer is frequently diagnosed at an advanced stage, making treatment particularly challenging. Recently, studies have indicated that G protein γ Subgene 7 (GNG7) likely has a significant impact on controlling cell proliferation, apoptosis, and migration in different cancers. However, the precise immunological regulatory mechanism of GNG7 in the development and advancement of lung adenocarcinoma (LUAD) remains largely uncharted. Analyzing TCGA databases, we discovered an inverse relationship between GNG7 expression and tumor growth, alongside a poorer prognosis in LUAD patients with reduced GNG7 levels. The study shows a strong connection between GNG7 expression and immune cell infiltration, as well as important immune regulatory markers. This indicates that GNG7 could be used as a prognosis tool and a target for therapy. These insights underscore GNG7's importance in LUAD and its promise in guiding immune-based treatment strategies. Moreover, in vitro experiments revealed that overexpression of GNG7 significantly inhibited cell proliferation, invasion, and migration, while promoting apoptosis, further supporting its potential as a therapeutic target in LUAD. Leveraging the significant link between GNG7 and the immunological microenvironment, we developed a prognostic model encompassing immune-related genes modulated by GNG7. This model can not only predict the prognosis of lung adenocarcinoma but also forecast the patient's response to immunotherapy. This research result was verified through the GSE31210 and IMvigor210 cohorts. Ultimately, our research positions GNG7 as a pivotal marker for prognosis and a novel target for therapeutic intervention in LUAD management.
Keywords: GNG7, Lung Adenocarcinoma, Immune infiltration, Immunotherapy, Prognostic model
Received: 06 Mar 2025; Accepted: 29 Apr 2025.
Copyright: © 2025 Luo, Liu, Peng, Zhao, Li, Cai, Lei, Zhang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hongpan Zhang, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China
Yongsheng Zhao, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.